氨基甙类药物在抗结核治疗中的肾毒性评估

Renal Toxicity Assessment of Aminoglycoside Drugs in The Anti-TB Treatment

目的:评价在抗结核治疗中应用氨基甙类药物所引起的肾毒性。方法:将在我院接受治疗的结核病患者根据所使用抗生素的种类进行分类,选出治疗用药为氨基甙类的病患,视所用药物分组,分别为甲组(37例,卷曲霉素)、乙组(41例,丁胺卡那霉素)、丙组(34例,链霉素)、丁组(39例,卡那霉素),计算各组不同时间清除血清肌酐的速率,以评价各组的肾毒性。结果:甲组、乙组、丙组、丁组在治疗前的清除速率无有效差异(P>0.05);治疗后甲组和丁组的清除速率降低幅度大于乙组和丙组,但差异无效(P>0.05);各组不同时间内的清除速率无明显变化,浮动差异均无效(P>0.05)。结论:氨基甙类药物可在常规剂量下应用于抗结核的治疗中,不会造成肾功能损伤,相较之下,奈替米星和链霉素的肾毒性更小,用药更安全。

Objective：To evaluate the anti-TB treatment-induced renal toxicity of aminoglycoside drugs.Methods：TB patients will be treated in our hospital to be classified according to the type of antibiotics used to elect drug treatment aminoglycoside patients,depending on the drugs used in grouping,Group A（37 cases,capreomycin） group B（41 cases,amikacin）,C（34 cases,streptomycin）,the small group（39 cases,kanamycin）,each group was calculated at different times to clear the rate of serum creatinine,to evaluate groups of renal toxicity.Results：Group A,Group B,Group C,Group D no effective difference in the clearance rate in the pre-treatment（P0.05）;after treatment,the clearance rate of the Group A and Group D decrease greater than Group B and Group C,but the difference inactive（P0.05）;no significant changes in clearance rate within each group at different times,are invalid floating difference（P0.05）.Conclusion：Aminoglycoside drugs in conventional doses used in anti-TB treatment does not cause renal injury,contrast,Chennai for the renal toxicity of m star and streptomycin smaller,safer drugs.